[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:sstr2-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"SSTR2 Gene",5,4,[8,16,22,29,36],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06395402","177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry",[12],"Phase 2","RECRUITING","2026-08-26T02:15:45.413021Z","2026-05-05T02:43:29.074931Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT04529044","177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer",[12],"2026-08-26T02:19:16.454910Z","2026-05-05T02:43:27.762031Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT07129252","A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors",[26],"Phase 1\u002FPhase 2","2026-08-26T02:15:56.561131Z","2026-05-05T02:43:27.489197Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT04081701","68-Ga DOTATATE PET\u002FMRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.",[33],"Phase 4","2026-08-26T02:15:09.079045Z","2026-05-05T02:43:27.179150Z",{"nct_id":37,"title":38,"phases":39,"status":40,"updated_at":41,"content_modified":42},"NCT06991738","177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer",[26],"NOT_YET_RECRUITING","2026-08-26T02:18:31.164304Z","2026-05-05T02:43:27.508813Z"]